Queensland researchers are launching a world-first clinical trial aimed at improving recovery from spinal cord injuries.In the study, led by The University of Queensland and The Princess Alexandra (PA) Hospital, a new anti-inflammatory drug will be given to participants within hours of spinal trauma in an effort to minimise tissue damage.
Spinal cord patients also are at higher risk for cardiovascular disease; pneumonia; life-threatening blood clots; bladder, bowel and sexual dysfunction; constipation and other gastrointestinal problems; pressure ulcers; and chronic pain, according to a report published in the journal Current Neurology and Neuroscience Reports.
A new study reports that PJK risk following lumbar spinal fusion depends on the level of the spine fused. Specifically, the authors – who include members of the International Spine Study Group (ISSG) from multiple academic centers – found that fusing the lower portion of lumbar spine results in a decreased risk of PJK.
A new therapy to treat spinal cord injuries in people who have lost all motor and sensory function below the injury site shows additional motor function improvement at 6-months and 9-months following treatment with 10 million AST-OPC1. The positive efficacy results from an ongoing research study were announced on Jan. 24 in a conference held by Asterias Biotherapeutics, Inc., the biotechnology company that manufactures AST-OPC1.